Chanaka Wijeratne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chanaka Wijeratne has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Brian Draper
University of New South Wales and Prince of Wales Hospital, Randwick, NSW 2031, Australia
1 shared publicationCarmelle Peisah
Northern Sydney Local Health District, Sydney, Australia
1 shared publication- Carmelle Peisah
University of New South Wales
1 shared publication Darren M. Lipnicki
School of Psychiatry, University of New South Wales, Sydney, Australia
1 shared publicationGeorgina Luscombe
1 shared publicationGin S. Malhi
CADE Clinic, Discipline of Psychiatry, Sydney Medical School, University of Sydney, Sydney, Australia
1 shared publication
Latest Publications
- 28 January 2016
- Published by SAGE Publications in Australasian Psychiatry
- Vol. 24 (2) , 140-143
Clinical assessment of the late-career medical practitioner
Objectives: This paper is a guide to the general psychiatric assessment of the late career medical practitioner (LCP) from a clinical viewpoint. Conclusions: Late career is a specific developmental stage in medical practitioners, a time of transition towards retirement. The treating psychiatrist should be mindful of the welfare of the practitioner, the public and the profession during the assessment, which is conducted from a complex therapeutic and regulatory viewpoint. It is important to assess the physical, psychological and cognitive health of the LCP. Although rates of burnout, depression and suicidal ideation are lowest in Australian doctors over 60, only a small minority of LCPs over 75 are likely to perform at a cognitive level similar to that of younger colleagues. There are a number of therapeutic challenges, including the practitioner’s acceptance of their own ageing.
- 28 January 2016
- Published by SAGE Publications in Australasian Psychiatry
- Vol. 24 (2) , 140-143
Clinical assessment of the late-career medical practitioner
Objectives: This paper is a guide to the general psychiatric assessment of the late career medical practitioner (LCP) from a clinical viewpoint. Conclusions: Late career is a specific developmental stage in medical practitioners, a time of transition towards retirement. The treating psychiatrist should be mindful of the welfare of the practitioner, the public and the profession during the assessment, which is conducted from a complex therapeutic and regulatory viewpoint. It is important to assess the physical, psychological and cognitive health of the LCP. Although rates of burnout, depression and suicidal ideation are lowest in Australian doctors over 60, only a small minority of LCPs over 75 are likely to perform at a cognitive level similar to that of younger colleagues. There are a number of therapeutic challenges, including the practitioner’s acceptance of their own ageing.
- 1 January 2015
- Published by American Psychological Association (APA)
Quality Use of Medications in Dementia Tool
- 1 January 2015
- Published by American Psychological Association (APA)
Quality Use of Medications in Dementia Tool
- 11 February 2013
- Published by SAGE Publications in Australian & New Zealand Journal of Psychiatry
- Vol. 47 (5) , 425-430
Accepting the challenges of ageing and retirement in ourselves: The need for psychiatrists to adopt a consensus approach
- 11 February 2013
- Published by SAGE Publications in Australian & New Zealand Journal of Psychiatry
- Vol. 47 (5) , 425-430
Accepting the challenges of ageing and retirement in ourselves: The need for psychiatrists to adopt a consensus approach
- Open Access
- 29 August 2012
- Published by Elsevier in International Psychogeriatrics
- Vol. 25 (1) , 54-60
Hippocampal and amygdala volumes in an older bipolar disorder sample
- 29 August 2012
- Published by Elsevier in International Psychogeriatrics
- Vol. 25 (1) , 54-60
Open AccessHippocampal and amygdala volumes in an older bipolar disorder sample
- 1 December 2011
- Published by SAGE Publications in Australian & New Zealand Journal of Psychiatry
- Vol. 45 (12) , 1026-1032
Reformulation of Current Recommendations for Target Serum Lithium Concentration According to Clinical Indication, Age and Physical Comorbidity
Background: There have been significant changes in the nature of psychiatric patient populations and patterns of drug prescribing in mood disorders since serum lithium monitoring was introduced. It seems opportune to review current guidelines for target lithium concentration given the decline in lithium monotherapy and increase in the numbers of older people and those with comorbid physical disease administered lithium. Method: A review was made of the literature of lithium monitoring and target serum concentration in mood disorders, older people, and comorbid physical illness. Results: Current guidelines, which generally recommend a target serum concentration of 0.5/0.6 to 1.1/1.2 mmol/L, have a number of limitations. A target lithium level of > 0.8 mmol/L is inappropriate given poor tolerability, and adequate efficacy when combination lithium-antipsychotic therapy is used at this or lower levels. Guidelines have largely failed to match specific clinical indications to serum levels, and to consider comorbid physical illness factors known to be associated with lithium toxicity. Conclusion: For most patients, a target serum lithium concentration range of 0.5–0.8 mmol/L, varying according to clinical indication, age and concurrent physical status, seems most appropriate in enhancing efficacy and minimizing adverse effects. The lower end of this range (0.5–0.6 mmol/L) is recommended for patients 50 years and over; those with diabetes insipidus, renal impairment or thyroid dysfunction; those administered diuretics, angiotensin converting enzyme (ACE) inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs)/COX-2 inhibitors; and in the prophylaxis of bipolar depression and management of acute unipolar depression. The higher end of this range (0.7–0.8 mmol/L) is recommended in the management of acute mania and prophylaxis of mania.
- 1 December 2011
- Published by SAGE Publications in Australian & New Zealand Journal of Psychiatry
- Vol. 45 (12) , 1026-1032
Reformulation of Current Recommendations for Target Serum Lithium Concentration According to Clinical Indication, Age and Physical Comorbidity
Background: There have been significant changes in the nature of psychiatric patient populations and patterns of drug prescribing in mood disorders since serum lithium monitoring was introduced. It seems opportune to review current guidelines for target lithium concentration given the decline in lithium monotherapy and increase in the numbers of older people and those with comorbid physical disease administered lithium. Method: A review was made of the literature of lithium monitoring and target serum concentration in mood disorders, older people, and comorbid physical illness. Results: Current guidelines, which generally recommend a target serum concentration of 0.5/0.6 to 1.1/1.2 mmol/L, have a number of limitations. A target lithium level of > 0.8 mmol/L is inappropriate given poor tolerability, and adequate efficacy when combination lithium-antipsychotic therapy is used at this or lower levels. Guidelines have largely failed to match specific clinical indications to serum levels, and to consider comorbid physical illness factors known to be associated with lithium toxicity. Conclusion: For most patients, a target serum lithium concentration range of 0.5–0.8 mmol/L, varying according to clinical indication, age and concurrent physical status, seems most appropriate in enhancing efficacy and minimizing adverse effects. The lower end of this range (0.5–0.6 mmol/L) is recommended for patients 50 years and over; those with diabetes insipidus, renal impairment or thyroid dysfunction; those administered diuretics, angiotensin converting enzyme (ACE) inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs)/COX-2 inhibitors; and in the prophylaxis of bipolar depression and management of acute unipolar depression. The higher end of this range (0.7–0.8 mmol/L) is recommended in the management of acute mania and prophylaxis of mania.
- 30 September 2011
- Published by Elsevier in Psychiatric Clinics of North America
- Vol. 34 (3) , 661-671
Somatization in Older People
- 30 September 2011
- Published by Elsevier in Psychiatric Clinics of North America
- Vol. 34 (3) , 661-671
Somatization in Older People
- Open Access
- 13 January 2009
- Published by Elsevier in International Psychogeriatrics
- Vol. 21 (2) , 330-337
Late life depression and dementia: a mental health literacy survey of Australian general practitioners
- 13 January 2009
- Published by Elsevier in International Psychogeriatrics
- Vol. 21 (2) , 330-337
Open AccessLate life depression and dementia: a mental health literacy survey of Australian general practitioners
- 1 February 2007
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 62 (2) , 153-158
The characteristics of fatigue in an older primary care sample
- 1 February 2007
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 62 (2) , 153-158
The characteristics of fatigue in an older primary care sample